在雌激素受体阳性乳腺癌中,SET-结合蛋白1 (SETBP1) 抑制细胞增殖
Yuki Ando1,2, Takaaki Masuda1,3, Naoki Hayashi1
1Department of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Breast cancer (Tokyo, Japan)
|February 20, 2025
概括
低SETBP1表达表明雌激素受体阳性乳腺癌的预后不佳. 这种下调促进了癌细胞的增殖,可能是通过MAPK信号传递.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- SETBP1基因促进分子多态 rs6507583与ER阳性乳腺癌有关.
- 在ER阳性乳腺癌中SETBP1表达的作用需要进一步研究.
研究的目的:
- 评估ER阳性乳腺癌中SETBP1表达的临床和生物学意义.
- 为了确定SETBP1表达水平是否与患者的结果和癌症进展相关.
主要方法:
- 在独立的乳腺癌队列中分析SETBP1表达和临床结果.
- 在瘤组织中定位SETBP1的免疫组织化学染色.
- 在体外测试包括SETBP1-敲击细胞中的增殖,PP2A活性和基因表达.
- 对途径关联和影响SETBP1mRNA表达的因素进行TCGA数据集分析.
- 目标测序和RT-qPCR用于在细胞系和组织中检查SETBP1和rs6507583.
主要成果:
- 与正常细胞相比,SETBP1在乳腺癌细胞中被下调.
- 低SETBP1mRNA表达是低无复发生存率的独立预测因素.
- SETBP1敲击增强了ER阳性乳腺癌细胞的增殖和MAPK酸化.
- SETBP1表达与E2F,MYC和G2M目标基因相反相关.
- 低SETBP1表达与促进物甲基化和DNA拷贝数删除有关.
- 在具有rs6507583多态的样本中,SETBP1的表达率较低.
结论:
- 减少SETBP1表达作为ER阳性乳腺癌的预后生物标志物.
- 低SETBP1表达促进瘤细胞增殖,可能通过MAPK通路激活.
相关概念视频
01:23Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:58Cell Specific Gene Expression
13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K